104 related articles for article (PubMed ID: 10694954)
1. Effects of bisphosphonate on experimental jaw metastasis model in nude mice.
Sasaki A; Nishiyama A; Alcalde RE; Lim DJ; Mese H; Nakayama S; Yokoyama S; Matsumura T
Oral Oncol; 1999 Sep; 35(5):523-9. PubMed ID: 10694954
[TBL] [Abstract][Full Text] [Related]
2. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice.
Sasaki A; Kitamura K; Alcalde RE; Tanaka T; Suzuki A; Etoh Y; Matsumura T
Int J Cancer; 1998 Jul; 77(2):279-85. PubMed ID: 9650565
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
[TBL] [Abstract][Full Text] [Related]
4. Experimental bone metastasis model of the oral and maxillofacial region.
Sasaki A; Yoneda T; Terakado N; Alcalde RE; Suzuki A; Matsumura T
Anticancer Res; 1998; 18(3A):1579-84. PubMed ID: 9673373
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor.
Hiraga T; Tanaka S; Yamamoto M; Nakajima T; Ozawa H
Bone; 1996 Jan; 18(1):1-7. PubMed ID: 8717529
[TBL] [Abstract][Full Text] [Related]
8. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions.
Peyruchaud O; Winding B; Pécheur I; Serre CM; Delmas P; Clézardin P
J Bone Miner Res; 2001 Nov; 16(11):2027-34. PubMed ID: 11697798
[TBL] [Abstract][Full Text] [Related]
9. [A case of brain abscess secondary to bisphosphonate-related osteonecrosis of the jaws in metastatic bone lesions from breast carcinoma].
Matsushita A; Kamigaki S; Nakamura Y
Gan To Kagaku Ryoho; 2013 May; 40(5):631-3. PubMed ID: 23863588
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of inhibitory effects by murine interferon gamma and a new bisphosphonate (alendronate) in hypercalcemic, nude mice bearing human tumor (LJC-1-JCK).
Tohkin M; Kakudo S; Kasai H; Arita H
Cancer Immunol Immunother; 1994 Sep; 39(3):155-60. PubMed ID: 7522963
[TBL] [Abstract][Full Text] [Related]
11. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis.
Hussein O; Tiedemann K; Komarova SV
Bone; 2011 Feb; 48(2):202-11. PubMed ID: 20849994
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by a new bisphosphonate (YM175) of bone resorption induced by the MBT-2 tumour of mice.
Nemoto R; Nishijima Y; Uchida K; Koiso K
Br J Cancer; 1993 May; 67(5):893-7. PubMed ID: 8494721
[TBL] [Abstract][Full Text] [Related]
13. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
Hiraga T; Williams PJ; Mundy GR; Yoneda T
Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
15. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
Buijs JT; Que I; Löwik CW; Papapoulos SE; van der Pluijm G
Bone; 2009 Feb; 44(2):380-6. PubMed ID: 19041433
[TBL] [Abstract][Full Text] [Related]
17. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma.
Yoneda T; Michigami T; Yi B; Williams PJ; Niewolna M; Hiraga T
Cancer; 2000 Jun; 88(12 Suppl):2979-88. PubMed ID: 10898341
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates and breast carcinoma: present and future.
Lipton A
Cancer; 2000 Jun; 88(12 Suppl):3033-7. PubMed ID: 10898348
[TBL] [Abstract][Full Text] [Related]
19. Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonate.
Sohara Y; Shimada H; Scadeng M; Pollack H; Yamada S; Ye W; Reynolds CP; DeClerck YA
Cancer Res; 2003 Jun; 63(12):3026-31. PubMed ID: 12810621
[TBL] [Abstract][Full Text] [Related]
20. Suppression by incadronate of invasion and growth of A-375 human melanoma in mandible in nude mice.
Kitagawa Y; Hiraga T; Yura Y; Yoneda T
Oncol Rep; 2005 Feb; 13(2):211-6. PubMed ID: 15643500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
